Streetbeat News

MBXBF

Microbix Biosystems Inc.

Industry

Research and Development in Biotechnology

Open

0.28

Mkt cap

40M

Volume

34K

High

0.28

P/E Ratio

28.00

52-wk high

0.39

Low

0.28

Div yield

N/A

52-wk low

0.20

Microbix and ACPCC are collaborating to support the elimination of cervical cancer in the Indo-Pacific region through the EPICC HPV Elimination Partnership. They are supplying PROCEEDxFLOQ QAPs to ensure test accuracy.

Portfolio Pulse from

March 17, 2025 | 11:15 am

Microbix Biosystems Inc. will present at the Whistler Capital Event conference in British Columbia from February 21-23, 2025. This event is an opportunity for Microbix to engage with equity investors.

Portfolio Pulse from

February 19, 2025 | 5:30 pm

Microbix Biosystems Inc. (MBXBF) held its Q1 2025 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

February 13, 2025 | 7:45 pm

Microbix Biosystems Inc. reported a strong performance for Q1 fiscal 2025, with a 40% year-over-year increase in revenues from its diagnostic-test related ingredients and devices businesses, leading to significant net income.

Portfolio Pulse from

February 13, 2025 | 1:00 pm

Microbix Biosystems Inc. (MBXBF) held its Q4 2024 earnings call, discussing the company's financial performance. Key participants included CEO Cameron Groome and CFO Jim Currie.

Portfolio Pulse from

December 19, 2024 | 8:00 pm

Microbix Biosystems Inc. reported record revenues for Q4 and fiscal year 2024, driven by a 42% increase in sales of its diagnostic-test related ingredients and devices. The company achieved significant net income growth.

Portfolio Pulse from

December 19, 2024 | 12:30 pm

Microbix has scheduled the release of its Q4 Fiscal 2024 results and a subsequent webinar discussion for December 19, 2024. This announcement is relevant for investors tracking the company's performance.

Portfolio Pulse from

December 12, 2024 | 12:15 pm

Microbix Biosystems Inc. has announced a Normal Course Issuer Bid to repurchase and cancel up to 5% of its outstanding common shares, aiming to enhance shareholder value.

Portfolio Pulse from

December 05, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.